{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T13:40:25Z","timestamp":1737726025249,"version":"3.33.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","elsevier.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.acuroe.2024.05.013","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T15:33:53Z","timestamp":1715700833000},"page":"674-682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Consensus update on the therapeutic approach to patients with neurogenic detrusor overactivity"],"prefix":"10.1016","volume":"48","author":[{"given":"A.","family":"Borau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Salinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Allu\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Castro-Diaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Arlandis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Virseda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Adot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.acuroe.2024.05.013_bib0005","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodyn."},{"issue":"4","key":"10.1016\/j.acuroe.2024.05.013_bib0010","doi-asserted-by":"crossref","first-page":"492","DOI":"10.4081\/aiua.2022.4.492","article-title":"Efficacy of overactive neurogenic bladder treatment: a systematic review of randomized controlled trials","volume":"94","author":"Bapir","year":"2022","journal-title":"Arch Ital Urol Androl."},{"issue":"5","key":"10.1016\/j.acuroe.2024.05.013_bib0015","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1055\/s-0040-1713876","article-title":"Neurogenic bladder: epidemiology, diagnosis, and management","volume":"40","author":"Panicker","year":"2020","journal-title":"Semin Neurol."},{"key":"10.1016\/j.acuroe.2024.05.013_bib0020","series-title":"StatPearls","article-title":"Neurogenic bladder and neurogenic lower urinary tract dysfunction","author":"Leslie","year":"2024"},{"issue":"3","key":"10.1016\/j.acuroe.2024.05.013_bib0025","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1310\/sci2503-195","article-title":"Medical management of neurogenic bladder for children and adults: a review","volume":"25","author":"Lucas","year":"2019","journal-title":"Top Spinal Cord Inj Rehabil."},{"issue":"8","key":"10.1016\/j.acuroe.2024.05.013_bib0030","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1002\/nau.23255","article-title":"Sacral neuromodulation for detrusor hyperactivity with impaired contractility","volume":"36","author":"Hennessey","year":"2017","journal-title":"Neurourol Urodyn."},{"key":"10.1016\/j.acuroe.2024.05.013_bib0035","first-page":"113","article-title":"Evaluation and management of overactive bladder: strategies for optimizing care","volume":"8","author":"Willis-Gray","year":"2016","journal-title":"Res Rep Urol."},{"issue":"1","key":"10.1016\/j.acuroe.2024.05.013_bib0040","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.acuro.2017.01.006","article-title":"A systematic review of the diagnosis and treatment of patients with neurogenic hyperactivity of the detrusor muscle","volume":"42","author":"Borau","year":"2018","journal-title":"Actas Urol Esp (Engl Ed)."},{"key":"10.1016\/j.acuroe.2024.05.013_bib0045","unstructured":"Blok B, Castro Diaz D, Del Popolo G, Gross T, Hamid R, Karsenty G, Kessler TM, Pannek, J. European Association of Urology (EAU) Guidelines on Neuro-Urology. 2023 (not-published); https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-Guidelines-on-Neuro-Urology-2023.pdf."},{"issue":"6","key":"10.1016\/j.acuroe.2024.05.013_bib0050","first-page":"E157","article-title":"Canadian Urological Association guideline: diagnosis, management, and surveillance of neurogenic lower urinary tract dysfunction - full text","volume":"13","author":"Kavanagh","year":"2019","journal-title":"Can Urol Assoc J."},{"key":"10.1016\/j.acuroe.2024.05.013_bib0055","unstructured":"Ficha t\u00e9cnica Toviaz\u00ae (fesoterodina). Pfizer Europe MA EEIG. London (United Kingdom): European Medicines Agency (EMA) [Internet]. 2007 Apr [cited 2023 June]. Available from: https:\/\/www.ema.europa.eu\/documents\/product-information\/toviaz-epar-product-information_es.pdf."},{"key":"10.1016\/j.acuroe.2024.05.013_bib0060","unstructured":"Ficha t\u00e9cnica Tovedeso\u00ae (desfesoterodina).Teva Pharma S.L.U. Madrid (Espa\u00f1a): Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS) [Internet]. 2018 Feb cited 2023 June]. Available from: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/82435\/FT_82435.html."},{"key":"10.1016\/j.acuroe.2024.05.013_bib0065","unstructured":"Center for Drug Evaluation and Research. Toviaz\u00ae (Fesoterodina). 022030. U.S. Food and Drug Administration (FDA) [Internet]. 2017 Nov [cited 2023 June]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/022030s014lbl.pdf."},{"issue":"9","key":"10.1016\/j.acuroe.2024.05.013_bib0070","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.acuro.2020.09.001","article-title":"AEU positioning statement on transdermal drug administration: determinant evolution of functional urologic therapy","volume":"44","author":"Esteban","year":"2020","journal-title":"Actas Urol Esp (Eng Ed)."},{"issue":"5","key":"10.1016\/j.acuroe.2024.05.013_bib0075","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/nau.22755","article-title":"Efficacy, safety, and tolerability of intravesically administered 0.1% oxybutynin hydrochloride solution in adult patients with neurogenic bladder: a randomized, prospective, controlled multi-center trial","volume":"35","author":"Schr\u00f6der","year":"2016","journal-title":"Neurourol Urodyn."},{"issue":"7","key":"10.1016\/j.acuroe.2024.05.013_bib0080","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/nau.23566","article-title":"Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-prospective, randomized, double-blind, placebo-controlled study","volume":"37","author":"Krhut","year":"2018","journal-title":"Neurourol Urodyn."},{"issue":"1","key":"10.1016\/j.acuroe.2024.05.013_bib0085","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/sc.2015.195","article-title":"Initial experience with the treatment of neurogenic detrusor overactivity with a new \u03b2-3 agonist (mirabegron) in patients with spinal cord injury","volume":"54","author":"W\u00f6llner","year":"2016","journal-title":"Spinal Cord."},{"issue":"2","key":"10.1016\/j.acuroe.2024.05.013_bib0090","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.eururo.2022.03.010","article-title":"Efficacy and safety of abobotulinumtoxina in patients with neurogenic detrusor overactivity incontinence performing regular clean intermittent catheterization: pooled results from two phase 3 randomized studies (CONTENT1 and CONTENT2)","volume":"82","author":"Kennelly","year":"2022","journal-title":"Eur Urol."},{"issue":"1","key":"10.1016\/j.acuroe.2024.05.013_bib0095","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/nau.25062","article-title":"AbobotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity regardless of spinal cord injury or multiple sclerosis etiology: Pooled analysis of two phase III randomized studies (CONTENT1 and CONTENT2)","volume":"42","author":"Denys","year":"2023","journal-title":"Neurourol Urodyn."},{"issue":"3","key":"10.1016\/j.acuroe.2024.05.013_bib0100","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11255-022-03107-6","article-title":"An indirect comparison meta-analysis of noninvasive intravesical instillation and intravesical injection of botulinum toxin-A in bladder disorders","volume":"54","author":"Yunfeng","year":"2022","journal-title":"Int Urol Nephrol."},{"issue":"9","key":"10.1016\/j.acuroe.2024.05.013_bib0105","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/iju.14602","article-title":"Botulinum toxin injections for Japanese patients with urinary incontinence caused by neurogenic detrusor overactivity: clinical evaluation of onabotulinumtoxinA in a randomized, placebo-controlled, double-blind trial with an open-label extension","volume":"28","author":"Honda","year":"2021","journal-title":"Int J Urol."},{"issue":"6","key":"10.1016\/j.acuroe.2024.05.013_bib0110","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.eururo.2010.09.024","article-title":"Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis","volume":"58","author":"Kessler","year":"2010","journal-title":"Eur Urol."},{"issue":"4","key":"10.1016\/j.acuroe.2024.05.013_bib0115","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s12325-021-01650-9","article-title":"Systematic literature review and meta-analysis of sacral neuromodulation (SNM) in patients with neurogenic lower urinary tract dysfunction (nLUTD): over 20 years\u2019 experience and future directions","volume":"38","author":"van Ophoven","year":"2021","journal-title":"Adv Ther."},{"key":"10.1016\/j.acuroe.2024.05.013_bib0120","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.wneu.2021.09.041","article-title":"Sacral anterior root stimulation and visceral function outcomes in spinal cord injury\u2013a systematic review of the literature over four decades","volume":"157","author":"Guiho","year":"2022","journal-title":"World Neurosurg."},{"issue":"8","key":"10.1016\/j.acuroe.2024.05.013_bib0125","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.neurom.2022.04.034","article-title":"Transcutaneous tibial nerve stimulation in the management of overactive bladder: a scoping review","volume":"25","author":"Sayner","year":"2022","journal-title":"Neuromodulation."},{"issue":"1","key":"10.1016\/j.acuroe.2024.05.013_bib0130","doi-asserted-by":"crossref","DOI":"10.3390\/toxins14010030","article-title":"Real-world data regarding satisfaction to botulinum toxin A injection into the urethral sphincter and further bladder management for voiding dysfunction among patients with spinal cord injury and voiding dysfunction","volume":"14","author":"Lee","year":"2022","journal-title":"Toxins (Basel)."},{"issue":"2","key":"10.1016\/j.acuroe.2024.05.013_bib0135","doi-asserted-by":"crossref","DOI":"10.3390\/toxins15020108","article-title":"Botulinum toxin A injection for autonomic dysreflexia-detrusor injection or urethral sphincter injection?","volume":"15","author":"Chow","year":"2023","journal-title":"Toxins (Basel)."},{"issue":"5","key":"10.1016\/j.acuroe.2024.05.013_bib0140","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1002\/jmv.26849","article-title":"Bladder and bowel incontinence in COVID-19","volume":"93","author":"Pourfridoni","year":"2021","journal-title":"J Med Virol."},{"issue":"5","key":"10.1016\/j.acuroe.2024.05.013_bib0145","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1002\/nau.24682","article-title":"Is coronavirus disease 2019 associated with indicators of long-term bladder dysfunction?","volume":"40","author":"Welk","year":"2021","journal-title":"Neurourol Urodyn."},{"issue":"1","key":"10.1016\/j.acuroe.2024.05.013_bib0150","first-page":"7","article-title":"[Urodynamic AUR in Guillain-Barr\u00e9 syndrome post-infection by coronavirus Sars-CoV-2. A bibliographic review]","volume":"75","author":"M\u00e9ndez-Rubio","year":"2022","journal-title":"Arch Esp Urol."}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578624000738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578624000738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T12:59:05Z","timestamp":1737723545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173578624000738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2173578624000738"],"URL":"https:\/\/doi.org\/10.1016\/j.acuroe.2024.05.013","relation":{},"ISSN":["2173-5786"],"issn-type":[{"type":"print","value":"2173-5786"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus update on the therapeutic approach to patients with neurogenic detrusor overactivity","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuroe.2024.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2024.04.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AEU. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}